Flavonoids as antiobesity agents: A review
- PMID: 33084093
- DOI: 10.1002/med.21740
Flavonoids as antiobesity agents: A review
Abstract
Obesity is a global health problem that affects all age groups in both developing and developed countries. In recent years, the prevalence of overweight and obesity has reached pandemic levels, resulting in a dramatic increase in the incidence of various comorbidities, such as cardiovascular diseases, type 2 diabetes, and cancer, consequently leading to massive health and socioeconomic burdens. Together with lifestyle changes, antiobesity pharmacotherapy is gaining momentum as an adjunctive treatment. However, the available pharmacological approaches have limited use owing to either significant adverse effects or low efficacy. Over the years, natural products have been an important source of lead compounds for drug discovery. Among these, flavonoids are associated with important biological effects and health-promoting activities. In this review, we discuss the modulatory effects of flavonoids on obesity and their potential mechanisms of action. The literature strongly suggests that most common flavonoids demonstrate a pronounced effect on obesity as shown by their ability to lower body weight, fat mass, and plasma triglycerides/cholesterol, both in in vitro and in vivo models. The impact of flavonoids on obesity can be observed through different mechanisms: reducing food intake and fat absorption, increasing energy expenditure, modulating lipid metabolism, or regulating gut microbiota profile. A better understanding of the known antiobesity mechanisms of flavonoids will enable their potential use to treat this medical condition. Therefore, this review focuses on the putative biological mechanisms through which flavonoids may prevent or treat obesity and highlights new perspectives on future pharmacological use.
Keywords: antiobesity mechanisms; drug discovery; flavonoids; lipid metabolism; obesity; obesogenic pathways.
© 2020 Wiley Periodicals LLC.
References
REFERENCES
-
- Brundtland GH. From the World Health Organization. Reducing risks to health, promoting healthy life. J Am Med Assoc. 2002;288(16):1974.
-
- Williams EP, Mesidor M, Winters K, Dubbert PM, Wyatt SB. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Curr Obes Rep. 2015;4(3):363-370.
-
- Akhlaghi M, Ghobadi S, Mohammad Hosseini M, Gholami Z, Mohammadian F. Flavanols are potential anti-obesity agents, a systematic review and meta-analysis of controlled clinical trials. Nutr Metab Cardiovasc Dis. 2018;28(7):675-690.
-
- Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016;22(7 suppl):s176-s185.
-
- Boles A, Kandimalla R, Reddy PH. Dynamics of diabetes and obesity: epidemiological perspective. Biochim Biophys Acta Mol Basis Dis. 2017;1863(5):1026-1036.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
